focus -WSS

focus

author：Wikipedia 2025-09-28 00:48:42 - browse：84

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Key House panel plots a new health care package

explore

WSS

A protest over insulin prices is seen as a fight for life

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

What’s missing from the debate over nursing home staff minimums

Why Novartis is going to walk from its acquisition of MorphoSys

Sanofi seeks simpler, safer CRISPR sickle cell cure

Adopting new red light myopia treatments may be short

knowledge

focus

focus

How to save PrEP access — and even expand it

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

State Dept. review finds Biden bears some blame for Afghanistan failures

Custom gene therapy hints at new path for rare disease treatments

United colonoscopy coverage change 'may cost lives,' doctors say

The CDC's new social media misinformation war

BioMarin wins approval for gene therapy to treat hemophilia A

Group opposing PBM reform sets lobbying record

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In early work, researchers turn to CRISPR to treat Alzheimer's

hotspot

Sanofi seeks simpler, safer CRISPR sickle cell cure

A single Democrat is willing to weaken Medicare negotiation power

AI gets buy

Key House panel plots a new health care package

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Wikipedia

explore

leisure time

explore